Immune Profiling for Cancer Immunotherapy Response

Inclusion Criteria

• •Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
• •Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).